Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 20Pancreatic Fistula 3Gastroparesis 2Bile Duct Neoplasms 2Recurrence 1Pancreatitis, Chronic 1Pancreatic Ductal Adenocarcinoma 1Non-alcoholic Fatty Liver Disease 1Jaundice, Obstructive 1Hypoxia 1Hemorrhage 1Gastrointestinal Stromal Tumor of Duodenum 1Fatty Liver 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 15pembrolizumab 12Capecitabine 12Fluorouracil 9Leucovorin 7Albumin-Bound Paclitaxel 7lenvatinib 6Radiofrequency Ablation 6Panitumumab 6130-nm albumin-bound paclitaxel 6Irinotecan 5Bevacizumab 5durvalumab 4Taxes 4Nivolumab 4Hepatectomy 4Drug Therapy 4tremelimumab 3apatinib 3Radiosurgery 3Platinum 3Injections 3Floxuridine 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3trametinib 2spartalizumab 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cholangiocarcinoma × Pancreaticoduodenectomy × Clear all
NCT04596865 2023-11-18

Recurrence After Whipple's (RAW) Study

University Hospital Plymouth NHS Trust

Completed
1,484 enrolled
Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms, Recurrence, Cholangiocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡